

TABLE 1 Overall Survival (OS) of children with a solid tumor in low- and middle-income countries reported between 2011 and 2016. Subgroup stratifications for survival statistics, if mentioned in the publication, are reported in the Risk or Treatment Group column under Overall Survival. Sample sizes reported in this table are the total number of patients included at the start of the study.

Disease	First Author	Publication Year	Country	Year Range of Diagnosis	Total Study Sample Size	Overall Survival	Risk or Treatment Group
Retinoblastoma	Chawla, B. ⁵	2016	India	2009 - 2013	600	83% at 1y	
						73% at 2y	
						65% at 5y	
	Gao, J. ⁶	2016	China	2006 - 2015	253	87.8% at 3y	
						81.4% at 5y	
						74.8% at 10y	
	Gao, Y.J. ⁷	2011	China	2005 - 2009	133	98% at 5y	
	Gündüz, K. ⁸	2013	Turkey	1998 - 2010	192	99% at 4y	intraocular
						60% at 4y	extraocular
	Huang, D. ⁹	2013	China	2005 - 2010	684	95.1% at 3y	
	Islam, F. ¹⁰	2013	Pakistan			66.2% at 1y	
	Kruger, M. ¹¹	2014	South Africa	2001 - 2008	73	68% at 5y	
	Luna-Fineman, S. ¹²	2012	AHOPCA	1999 - 2004	171	48% at 5y	
	Luo, X. ¹³	2015	China	2003 - 2011	314	80.9% at 5y	
	Ossandón, D. ¹⁴	2015	Chile	2007 - 2014	27	100% at 3y	
	Shah, P.K. ¹⁵	2015	India	2006 - 2011	106	93.1% at 1y	
						90.2% at 3y	
						89.2% at 5y	
	Subramaniam, S. ¹⁶	2014	Malaysia	2004 - 2012	119	76.7% at 1y	
	Waddell, K.M. ¹⁷	2015	Uganda	2006 - 2013	270	65% at 2y	
	Wongmas, P. ¹⁸	2015	Thailand	1990 - 2009	75	60% at 5y	
	Yizhuo, W. ¹⁹	2014	China	2006 - 2012	537	95.3% at 5y	
Germ Cell Tumor	Fedhila, F. ²⁰	2016	Tunisia	1998 - 2012	33	82% at 2y	
						75% at 5y	
	Lopes, L.F. ²¹	2016	Brazil	1999 - 2009	579	90% at 10y	intermediate risk, good

							response
						74.1% at 10y	intermediate risk, partial response
						66.8% at 10y	high risk, good response
						74.8% at 10y	high risk, partial response
Hepatoblastoma	Yuan, X.J. ²²	2016	China	2006 - 2013	153	83.3% at 5y	
	Tannuri, A.C. ²³	2015	Brazil	1993 - 2014	58	86% at 5y	
Rhabdomyo- sarcoma	Sezgin, G. ²⁴	2015	Turkey	2000 - 2011	24	68.2% at 2y	carboplatin
						68.2% at 5y	carboplatin
						78% at 2y	non-carboplatin
						40% at 5y	non-carboplatin
	Ma, X. ²⁵	2015	China	2001 - 2014	161	72% at 5y	
						65.3% at 10y	
	Babaei, M. ²⁶	2015	Iran	2006 - 2013	30	87% at 1y	
						69% at 3y	
						50% at 5y	
	Al-Jumaily, U. ²⁷	2013	Jordan	2004 - 2008	45	72% at 4y	
	Badr, M.A. ²⁸	2012	Egypt	2004 - 2009	41	56.9% at 5y	
	Salman, M. ²⁹	2012	Lebanon	2002 - 2010	23	83% at 5y	
Osteosarcoma	Pruksakorn, D. ³⁰	2015	Thailand	1996 - 2013	144	37.9% at 5y	
						33.6% at 10y	
	Choeyprasert, W. ³¹	2014	Thailand	2003 - 2011	34	70.2% at 1y	
						51.8% at 2y	
						47.1% at 3y	
						44.8% at 5y	
	Petrilli, A.S. ³²	2013	Brazil	1991 - 2005	553	49% at 5y	
	Tan, P.X. ³³	2012	China	1998 - 2008	120	61.8% at 5y	
Ewing Sarcoma	Brunetto, A.L. ³⁴	2015	Brazil	2003 - N/A	175	54.4% at 5y	
	Abou Ali, B. ³⁵	2014	Lebanon	1999 - 2012	39	69% at 5y	
Kaposi Sarcoma	El-Mallawany, N. K. ³⁶	2016	Malawi	2010 - 2013	70	58% at 2y	
	Cox, C. M. ³⁷	2013	Malawi & Botswana	2003 - 2009	69	43% at 1y	

Neuroblastoma	Moreno, F. ³⁸	2016	Argentina	2000 - 2012	971	47% at 5y	
	Al-Tonbary, Y. ³⁹	2015	Egypt	2005 - 2009	132	47.6% at 2y	males
						10.4% at 2y	females
	Bordbar, M. ⁴⁰	2014	Iran	2006 - 2013	36	30.8% at 5y	
	Agarwala, S. ⁴¹	2014	India	1996 - 2009	144	60.7% at 5y	
	Li, K. ⁴²	2012	China	2000 - 2006	98	80% at 5y	stage 1 and 2
						48.3% at 5y	stage 3
						20% at 5y	stage 4
Soft Tissue Sarcoma	Boam, T. ⁴³	2016	Cambodia	2004 - 2014	40	58% at 1y	
						16% at 3y	
						10% at 5y	
	Farfalli, G.L. ⁴⁴	2014	Argentina	2000 - 2010	29	72% at 5y	
Wilms Tumor	Joannon, P. ⁴⁵	2016	Chile	1999 - 2013	226	89.9% at 5y	
	Rabeh, W. ⁴⁶	2016	Lebanon	2002 - 2013	35	88.6% at 3y	
	Verma, N. ⁴⁷	2016	India	2005 - 2014	108	74% at 5y	
	Stones, D. K. ⁴⁸	2015	South Africa	2000 - 2010	416	66% at 5y	
	Fawzy, M. ⁴⁹	2015	Egypt	2005 - 2010	100	75% at 3y	double loss of heterozygosity
						92% at 3y	chromosome 16q loss of heterozygosity
						93% at 3y	chromosome 1p loss of heterozygosity
						97% at 3y	negative loss of heterozygosity
	Pan, C. ⁵⁰	2015	China	1998 - 2012	142	83% at 5y	
	Cai, J. Y. ⁵¹	2014	China	1998 - 2012	316	72% at 5y	
	Acipayam, C. ⁵²	2014	Turkey	2005 - 2011	48	90% at 2y	carboplatin
						90% at 4y	carboplatin
						100% at 2y	non-carboplatin
						88% at 4y	non-carboplatin
	Moreira, C. ⁵³	2012	Senegal	2001 - 2004	133	71.6% at 5y	
	Israels, T. ⁵⁴	2012	Malawi	2006 - 2011	73	46% at 3y	
	Yao, W. ⁵⁵	2012	China	1998 - 2008	67	81% at 4y	